November 23, 2011 / 9:43 AM / 9 years ago

India's Biocon sees oral insulin partner by March

(For other news from the Reuters India Investment Summit, click here)

BANGALORE, Nov 23 (Reuters) - Biocon Ltd, India’s largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday .

“We are in advanced discussions with potential partners,” Biocon’s Managing Director Kiran Mazumdar-Shaw told the Reuters India Investment Summit in Bangalore.

In January, Biocon had said it was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes.

Mazumdar-Shaw, however, declined to name any potential partners.

She also said the planned IPO of its contract research organisation, Syngene, was on track.

(For summit blog:

For more on the Reuters India Investment Summit, see Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below